ENDONOVO THERAPEUTICS, INC. Total Assets

• ENDONOVO THERAPEUTICS, INC. showed a decrease of -36.2% in Total Assets from 2021 to 2022.
• This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
• XBRL data for this metric is available from 2010 to 2022 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2011: $993.4 thousand | Q1 2012: $2.2 thousand | Q1 2012: $1.03 million | Q2 2012: $988.0 thousand | Q3 2012: $968.5 thousand | Q4 2012: $78.1 thousand | Q3 2013: $63.9 thousand | Q2 2015: $53.7 thousand | Q3 2015: $61.8 thousand | Q2 2016: $102.4 thousand | Q3 2016: $264.5 thousand | Q1 2017: $358.4 thousand | Q2 2017: $203.4 thousand | Q3 2017: $160.2 thousand | Q1 2018: $4.47 million | Q2 2018: $4.28 million | Q3 2018: $4.71 million | Q1 2019: $3.77 million | Q2 2019: $4.12 million | Q3 2019: $3.41 million | Q1 2020: $3.07 million | Q2 2020: $2.90 million | Q3 2020: $2.73 million | Q1 2021: $2.52 million | Q2 2021: $2.27 million | Q3 2021: $2.14 million | Q1 2022: $1.82 million | Q2 2022: $1.59 million | Q3 2022: $1.45 million | Q4 2022: $1.28 million | Q1 2023: $1.20 million | Q2 2023: $1.01 million | Q3 2023: $815.8 thousand.
• Over the full 11 years of available data (2010 to 2022), ENDONOVO THERAPEUTICS, INC.'s Total Assets has grown by 662.9%.
• Historical annual values: Fiscal year 2022: $1.28 million | Fiscal year 2021: $2.01 million | Fiscal year 2020: $2.61 million | Fiscal year 2019: $3.27 million | Fiscal year 2018: $4.24 million | Fiscal year 2017: $4.61 million | Fiscal year 2016: $318.7 thousand | Fiscal year 2015: $409.4 thousand | Fiscal year 2014: $45.6 thousand | Fiscal year 2011: $73.3 thousand | Fiscal year 2010: $168.0 thousand.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026